Treating people with IBS: a randomised double-blind placebo controlled trial of IntestAidIB in people with Irritable Bowel Syndrome (IBS)
| ISRCTN | ISRCTN67764449 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN67764449 |
| Protocol serial number | N/A |
| Sponsor | University of East London (UK) |
| Funder | Wyreside Products Limited |
- Submission date
- 13/12/2005
- Registration date
- 15/12/2005
- Last edited
- 22/04/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Christine Dancey
Scientific
Scientific
University of East London
School of Psychology
Romford Road
London
E15 4LZ
United Kingdom
| Phone | +44 (0)208 223 4497 |
|---|---|
| C.P.Dancey@uel.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised double-blind placebo-controlled cross-over study |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study objectives | H1: treatment with a nucleotide supplement will significantly improve symptoms of irritable bowel syndrome when compared to placebo H2: psychological measures (depression; anxiety) will predict improvement in symptomatology H3: improvements in symptoms will be accompanied by improvements in psychological state, e.g. anxiety and depression |
| Ethics approval(s) | Approved by the University of East London ethics committee. |
| Health condition(s) or problem(s) studied | Irritable Bowel Syndrome (IBS) |
| Intervention | Treatment by nucleotide supplements for 8 weeks and placebo for 8 weeks |
| Intervention type | Other |
| Primary outcome measure(s) |
Improvement in daily ratings of seven symptoms of IBS (self report) above placebo level. |
| Key secondary outcome measure(s) |
Improvement in anxiety and depression ratings (self report) following experimental condition. |
| Completion date | 30/09/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 40 |
| Key inclusion criteria | Participants should be aged 1865, should have been diagnosed as having IBS by a qualified medical practitioner, and should have diarrhoea as a main symptom. |
| Key exclusion criteria | Any other co-existing illnesses, and non-confirmation of the diagnosis by GP. |
| Date of first enrolment | 01/10/2004 |
| Date of final enrolment | 30/09/2005 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
University of East London
London
E15 4LZ
United Kingdom
E15 4LZ
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | Results | 08/06/2006 | Yes | No |